BCD-248
/ Biocad
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 04, 2026
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
(clinicaltrials.gov)
- P3 | N=390 | Recruiting | Sponsor: Biocad
New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology
February 04, 2025
FLAMMINGO: An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=100 | Recruiting | Sponsor: Biocad | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 2
Of
2
Go to page
1